
This builds on a recently announced clinical collaboration between AstraZeneca and Summit to advance cancer treatments

As the oncology landscape continues to evolve, life sciences organizations face a growing challenge: how do you communicate increasingly complex science in a way that creates meaningful engagement?

NETs affect approximately seven per 100,000 people in Scotland

Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.

Following ASCO® 2026, Inizio's experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year's congress revealed for pharmaceutical organisations. Together, they...

The deal expands the company’s rare disease portfolio

Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.

The companies plan to research and develop 12 new cancer treatments

The treatment is currently being evaluated in a phase 1/2 multicentre clinical study

The acquisition builds on Gilead’s oncology pipeline, focused on addressing areas of high unmet need

Werner previously held senior roles at Bristol Myers Squibb, AstraZeneca and Novartis

Lefranc has served at Ipsen since 2013, most recently as Senior Vice President